MX2020004218A - Métodos y composiciones para inhibir las actividades biológicas de adam10. - Google Patents

Métodos y composiciones para inhibir las actividades biológicas de adam10.

Info

Publication number
MX2020004218A
MX2020004218A MX2020004218A MX2020004218A MX2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A
Authority
MX
Mexico
Prior art keywords
adam10
biological activities
methods
peptides
inhibiting
Prior art date
Application number
MX2020004218A
Other languages
English (en)
Inventor
Marcia L Moss
Robert Rasmussen
Chris Prince
Original Assignee
Verra Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verra Therapeutics filed Critical Verra Therapeutics
Publication of MX2020004218A publication Critical patent/MX2020004218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24081—ADAM10 endopeptidase (3.4.24.81)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporcionan péptidos moduladores de ADAM10 aislados modificados y métodos de uso de los mismos para modular las actividades biológicas de ADAM10, inhibir las actividades biológicas de ADAM10 asociadas a enfermedades, trastornos o afecciones en sujetos, incluyendo, pero sin limitación la reducción de la inflamación y la inhibición de la proliferación de células indeseables. En algunas realizaciones, los péptidos moduladores de ADAM10 aislados modificados se basan en la SEQ ID NO: 3 o la SEQ ID NO: 4, y en algunas realizaciones incluyen modificaciones en o cerca de los extremos N-terminal y/o C-terminal de los péptidos desvelados, así como sustituciones, inserciones y deleciones en una o más de las posiciones de los aminoácidos de los péptidos de prodominio de ADAM 10 desvelados en el presente documento.
MX2020004218A 2017-10-02 2018-10-02 Métodos y composiciones para inhibir las actividades biológicas de adam10. MX2020004218A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566580P 2017-10-02 2017-10-02
US201762589842P 2017-11-22 2017-11-22
PCT/US2018/053938 WO2019070685A1 (en) 2017-10-02 2018-10-02 METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10

Publications (1)

Publication Number Publication Date
MX2020004218A true MX2020004218A (es) 2020-11-11

Family

ID=65995419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004218A MX2020004218A (es) 2017-10-02 2018-10-02 Métodos y composiciones para inhibir las actividades biológicas de adam10.

Country Status (8)

Country Link
US (3) US20190345473A1 (es)
EP (1) EP3691671A4 (es)
JP (2) JP7448219B2 (es)
AU (1) AU2018345601B2 (es)
CA (1) CA3077694A1 (es)
IL (1) IL273725A (es)
MX (1) MX2020004218A (es)
WO (1) WO2019070685A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276359B2 (en) 2018-01-31 2025-01-01 Verra Therapeutics Methods and compounds for preventing biological activity of a human9
US20220213169A1 (en) * 2019-05-09 2022-07-07 Verra Therapeutics, Llc Methods and compositions for inhibiting adam8 biological activities
JP2025507975A (ja) * 2022-03-08 2025-03-21 ノバ サウスイースタン ユニバーシティー ディスインテグリンおよびメタロプロテアーゼ１０（ａｄａｍ１０）の酵素・基質選択的エキソサイト阻害剤を用いた関節リウマチ（ｒａ）の処置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270625A1 (en) 2002-09-11 2004-04-30 Justus-Liebig-Universität Giessen Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
CN1822851B (zh) * 2003-05-15 2011-04-13 塔夫茨大学信托人 肽和多肽药物的稳定类似物
NZ556561A (en) 2005-02-02 2011-08-26 Macrogenics West Inc Adam-9 modulators
AU2006235260A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. ADAM10 in cancer diagnosis, detection and treatment
US7638301B2 (en) * 2006-08-28 2009-12-29 Biozyme, Inc. Prodomain modulators of ADAM 10
US20090285840A1 (en) 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
US8079782B1 (en) 2008-05-16 2011-12-20 Hilfiker William K Semi-extensible steel soil reinforcements for mechanically stabilized embankments
US9150865B2 (en) 2010-11-09 2015-10-06 The University Of Chicago Role of ADAM10 and its relevance to disease and therapeutics
WO2012088105A2 (en) * 2010-12-20 2012-06-28 Biozyme Inc. Methods and compositions for predicting disease status in cancer
WO2015117199A1 (en) 2014-02-04 2015-08-13 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers

Also Published As

Publication number Publication date
EP3691671A1 (en) 2020-08-12
JP2021500321A (ja) 2021-01-07
WO2019070685A1 (en) 2019-04-11
US20230203468A1 (en) 2023-06-29
AU2018345601B2 (en) 2025-05-15
AU2018345601A1 (en) 2020-05-21
US20250207119A1 (en) 2025-06-26
IL273725A (en) 2020-05-31
US12297469B2 (en) 2025-05-13
US20190345473A1 (en) 2019-11-14
JP7448219B2 (ja) 2024-03-12
EP3691671A4 (en) 2022-01-19
JP2024012470A (ja) 2024-01-30
CA3077694A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
EP4230644A3 (en) Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
UY37563A (es) Aislados de bacillus y usos de los mismos
MX2019011592A (es) Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
BR112018001761A2 (pt) uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética
ES2688030T3 (es) Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2020004218A (es) Métodos y composiciones para inhibir las actividades biológicas de adam10.
PH12013502609A1 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
WO2015183890A3 (en) Methods and compositions for the treatment of metabolic disorders and diseases
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
NZ774126A (en) Spd-1 variant - fc fusion proteins
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
NZ610620A (en) Inhibitors of apoptosis and uses thereof
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
MX2015002994A (es) Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
MX2015005102A (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
CU24746B1 (es) Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular
MX2017010259A (es) Proteina resistente a herbicidas, gen codificante y uso de los mismos.
MX2020008120A (es) Metodos y composiciones para inhibir las actividades biologicas de adam9.